Diagnosis and treatment of carcinoma of unknown primary

Abstract

Abstract:The primary focal area of carcinoma of unknown primary (CUP) can not be determined by clinical examination. It is difficult to find the primary site and its prognosis is poor. The traditional diagnostic approaches mainly include pathological examination, endoscopy, imaging technology and so on. However, positron emission tomography is the preferred approach. In recent years, gene expression profiling has become a new diagnostic approach to find the source of CUP. The detection rate by gene expression profiling is high, and the approach can accurately identify the primary site. The recommended therapies include classic platinum or paclitaxelbased chemotherapy, radiotherapy or surgery, and sitedirected therapy by gene expression profiling for patients with CUP improves their survival rate.

Key words:Neoplasms, unknown primary,Gene expression profiling,Diagnosis,Therapy

Li Zhenzhen, Xie Conghua. Diagnosis and treatment of carcinoma of unknown primary[J]. Journal of International Oncology, 2015, 42(12): 942-945.

References

［1］ Kou XG, Liang DL, Zhang QQ, et al. Analysis of prognostic factors in 68 patients with cancer of unknown primary site［J］. Zhonghua Zhong Liu Za Zhi, 2011, 33(10): 783-786. ［2］ Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP)［J］. Crit Rev Oncol Hematol, 2009, 69(3): 271-278. ［3］ Varadhachary GR, Abhruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer［J］. Cancer, 2004, 100(9): 1776-1785. ［4］ Molina R, Bosch X, Auge JM, et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site［J］. Tumor Biol, 2012, 33(2): 463-474. ［5］ Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4): 212-236. ［6］ Kwee TC, Basus, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary ［J］. Eur J Nucl Med Mol Imaging, 2010, 37(3): 635-644. ［7］ Hemminki K, Ji J, Sundquist J, et al. Familial risks in cancer of unknown primary: tracking the primary sites［J］. J Clin Oncol, 2011, 29(4): 435-440. ［8］ Pavilidis N, Pentheroudakis G. Cancer of unknown primary site［J］. Lancet, 2012, 379(9824): 1428-1435. ［9］ Kwee TC, Kwee RM. Combined FDGPET/CT for the detection of unknown primary tumors: systematic review and metaanalysis［J］. Eur Radiol, 2009, 19(3): 731-744. ［10］ Hainswroth JD, Rubin MS, Spiqel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct sitespecific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute［J］. J Clin Oncol, 2013, 31(2): 217-223. ［11］ Wang Y, Li YM, Yin YF. Clinical value of 18FFDG PET/CT in detection of original disease of patients with malignant ascites［J］. Chin J Med Imaging Technol, 2012, 28(12): 2193-2196. ［12］Roh JL, Kim JS, Lee JH, et al. Utility of combined 18FFDG PET/CT in patients with cervical metastases from unknown primary tumors［J］. Oral Oncol, 2009, 45(3): 218-224. ［13］Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDGPET scans in various thoracic diseases［J］. Korean J Radiol, 2006, 7(1): 57-69. ［14］MercierVogel L, Couson F, Kohlik M, et al. Impact of breast MRI and PETCT in breast cancer staging［J］. Rev Med Suisse, 2010, 6(250): 1076-1078. ［15］Dong MJ, Zhao K, Lin XT, et al. Role of FDG PET versus FDGPET/CT in detection of unknown primary tumor: a metaanalysis of the literature［J］. Nucl Med Commun, 2008, 29(9): 791-802. ［16］Greco FA. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management［J］. Curr Treat Options Oncol, 2013, 14(4): 634-642. ［17］Keller F, Psychogios G, Linke R, et al. Carcinoma of unknown primary in the head and neck: comparison between PET and PET/CT［J］. Head Neck, 2011, 33(11): 1569-1575. ［18］Monzon FA, LyonsWeiler M, Buturovic LJ, et al. Multicenter validation of a 1,550gene expression profile for identification of tumor tissue of origin［J］. J Clin Oncol, 2009, 27(15): 2503-2508. ［19］Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNAbased qRTPCR test for accurate identification of tumor tissue origin［J］. Mod Pathol, 2010, 23(6): 814-823. ［20］Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction［J］. Oncologist, 2010, 15(5): 500-506. ［21］Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognosis factors［J］. Semin Oncol, 2009, 36(1): 65-74. ［22］Culine S. Prognostic factors in unknown primary cancer［J］. Semin Oncol, 2009, 36(1): 60-64. ［23］Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors［J］. Semin Oncol, 2009, 36(1): 44-51. ［24］Escudier B, Bellmunt J, Négrier S, et al. Phase Ⅲ trial of bevacizumal plus interferon alfa2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival［J］. J Clin Oncol, 2010, 28(13): 2144-2150.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.